Business Description
Scribe Therapeutics is a clinical-stage biotech company based in Alameda, California, that develops gene-based treatments for serious diseases, with a particular focus on heart and metabolic conditions. The company uses its own proprietary CRISPR technology to silence or edit specific genes that drive disease at its source, without necessarily altering the underlying DNA. Its current pipeline includes three programs targeting genes linked to high cholesterol and elevated cardiovascular risk. Founded in 2017, Scribe is working toward treatments that could offer patients lasting relief from a single course of therapy.
